IJSRSET184485 | Received : 05 March | Accepted : 16 March 2018 | March-April-2018 [(4) 4 : 300-303 ] © 2018 IJSRSET | Volume 4 | Issue 4 | Print ISSN: 2395-1990 | Online ISSN : 2394-4099 Themed Section : Engineering and Technology 300 Drug Profile of Emtricitabine and Tenofovir AF N. MD. Akram 1 , Dr. M. Umamahesh 2 1 Research Scholar, Department of Chemistry, Rayalaseema University, Kurnool, Andhra Pradesh, India 2 Professor & HOD of chemistry, Rajeev Gandhi Memorial College of Engineering & Technology (RGMCET), Nandyal, Kurnool (Dt). Andhra Pradesh, India ABSTRACT Emtricitabine and Tenofovir alafenamide (tenofovir AF) is a novel oral prodrug of the nucleos(t)ide reverse transcriptase inhibitor (NRTI) tenofovir that has several pharmacological advantages over tenofovir disoproxil fumarate (tenofovir DF), including increased plasma stability and reduced tenofovir systemic exposure. Tenofovir AF has been coformulated with emtricitabine for the treatment of adults and adolescents with HIV-1 infection. Keywords: Emtricitabine, Tenofovir alafenamide, NRTI. I. INTRODUCTION Drug Profile of Emtricitabine Molecular structure Figure 1. Structure of Emtricitabine IUPAC Name 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3- oxathiolan-5-yl]-1,2- dihydropyrimidin-2-one. CAS Number 143491-57-0 Drug Bank DB00879 (APRD00226) Molecular formula C8H10FN3O3S Molecular weight 247.248 gm/mol Category Antiretroviral Description Emtricitabine is a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection in adults.